SCHEMBL201788

SCHEMBL201788

CCOC(=O)c1csc(-c2ccc(OC)cc2)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.67
GAA P10253 2/20 0.67
MAPT P10636 6/20 0.65
NPC1 O15118 5/20 0.65
HSP90AA1 P07900 1/20 0.65
POLB P06746 3/20 0.57
PKM P14618 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
RXFP1 Q9HBX9 1/20 0.57
CLK1 P49759 1/20 0.57
ALDH1A1 P00352 5/20 0.56
KDM4E B2RXH2 3/20 0.56
HPGD P15428 1/20 0.56
TLR7 Q9NYK1 1/20 0.55
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
GABRA2 P47869 1/20 0.52
GABRB2 P47870 1/20 0.52
TARBP2 Q15633 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29660366 0.89 RAB9A (0.67) RAB9AGAAMAPTNPC1HSP90AA1
SCHEMBL12582252 0.87 RAB9A (0.72) RAB9AGAAMAPTNPC1HSP90AA1
SCHEMBL27108838 0.87 RAB9A (0.72) RAB9AGAAMAPTNPC1HSP90AA1
SCHEMBL27108642 0.86 RAB9A (0.61) RAB9AGAAMAPTNPC1HSP90AA1
SCHEMBL28154886 0.86 RAB9A (0.70) RAB9AGAAMAPTNPC1HSP90AA1
SCHEMBL14481411 0.86 TLR7 (0.63) RAB9AGAAMAPTNPC1POLB
SCHEMBL4772500 0.86 RAB9A (0.63) RAB9AGAAMAPTNPC1HSP90AA1
SCHEMBL29660343 0.86 RAB9A (0.63) RAB9AGAAMAPTNPC1HSP90AA1
SCHEMBL29911190 0.85 RAB9A (0.66) RAB9AGAAMAPTNPC1HSP90AA1
SCHEMBL998829 0.85 RAB9A (0.69) RAB9AGAAMAPTNPC1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111848545-B 1- (2- (4-methoxyphenyl) thiazole-4-yl) ethylamine and synthetic method thereof 南通大学 2022-08-12 CN claimed
EP-4003955-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-06-01 EP claimed
CN-111848545-A 1- (2- (4-methoxyphenyl) thiazole-4-yl) ethylamine and synthetic method thereof 南通大学 2020-10-30 CN claimed
US-20260062407-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2026-03-05 US disclosed
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2025-12-18 US disclosed
EP-4577211-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER Wake Forest University Health Sciences (US) 2025-07-02 EP disclosed
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
US-20250011316-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES 2025-01-09 US disclosed
WO-2024044744-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed
WO-2024044744-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed
US-20220289698-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-09-15 US disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 EP disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
EP-2078003-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2009-07-15 EP disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 EP disclosed
WO-2008054702-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-05-08 WO disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062407-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX3, PRDX2 RAB9A 1459/4885GAA 4625/4885MAPT 4676/4885
US-20220289698-A1 INHIBITORS OF HUMAN ATGL LIPC, LIPG, PNLIP RAB9A 3552/4885GAA 101/4885MAPT 2152/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 RAB9A 2799/4885GAA 4454/4885MAPT 4784/4885
US-20250011316-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 RAB9A 2759/4885GAA 3275/4885MAPT 4743/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 RAB9A 2799/4885GAA 4454/4885MAPT 4784/4885
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 RAB9A 2949/4885GAA 3416/4885MAPT 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.